Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.